Portola announces positive Phase II results of andexanet alfa with Xarelto

USA-based Portola Pharmaceuticals (Nasdaq: PTLA) has announced positive results from the first part of Phase III trial of adexanet alfa withg German pharma major Bayer's (BAYN: DE) Factor Xa inhibitor Xarelto (rivaroxaban).

The study met its primary endpoint, and showed that andexanet alfa administered as an intravenous bolus significantly and immediately reversed the steady-state anticoagulation activity of Xarelto and was well-tolerated.

Portola is developing andexanet alfa, a US Food and Drug Administration-designated breakthrough therapy, as a universal antidote for patients treated with oral and injectable Factor Xa inhibitors who are experiencing a major bleeding episode or who require emergency surgery.